This study will evaluate a potential gene therapy treatment in which a targeted gene directly to the retina.
Vitreous Retina Macula Consultants of New York (VRMNY) has been selected to participate in a wet AMD study in collaboration with Regenxbio. VRMNY will be the only Manhattan-based site to participate in the study.1
This study will evaluate a potential gene therapy treatment in which a targeted gene directly to the retina, in order for these cells to produce an anti-VEGF protein, potentially reducing, or even eliminating, the frequent need for anti-VEGF injections. Currently, anti-VEGF injections are the standard of care and are needed frequently to treat wet AMD and require a significant commitment of time and resources on behalf of both patients and their physicians.1
Richard F. Spaide, MD, an ophthalmologist at VRMNY, shared his hopes for the future of this treatment and how it may lower the treatment burden for patients with wet AMD in the press release, saying, "This research represents a leap forward in the field of ophthalmology. We are hopeful that a one-time gene therapy administration might change the treatment landscape for wet AMD patients, freeing them from the repetitive anti-VEGF injections."1
VRMNY those affected by wet AMD to schedule an appointment with their research team to determine their eligibility to be a part of this study.
About Vitreous Retina Macula Consultants of New York
The group of ophthalmologists at Vitreous Retina Macula Consultants of New York are internationally known leaders in diagnosing and treating retinal diseases, known as the top New York experts and among the best-rated retina specialists in NYC. In our private practice, physicians prioritize high-quality, individualized eye care while utilizing cutting-edge diagnostic and therapeutic strategies. VRMNY doctors are proud to be on Newsweek's list of 350 best ophthalmologists and optometrists in the USA. For more information: https://www.vrmny.com/